About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5141084
Allelic
Composition
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
Genetic
Background
B6.129P2-Mtss1Gt(CSC156)Byg
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mtss1Gt(CSC156)Byg mutation (0 available); any Mtss1 mutation (76 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg cells display a distinct morphology and altered actin cytoskeleton reorganization

mortality/aging
• most mutants die between 14 and 24 months of age

neoplasm
• about 70% of mutants develop enlarged lymph notes or spleens infiltrated by abnormal lymphoid cells with vesicular nuclei, abundant cytoplasm and small nucleoli indicative of diffuse large B cell lymphoma; tumor cells are derived from CD5+ B-cells

hematopoietic system
• marker analysis of early B-cell development indicates a 35% increase in the percentage of pre-B2 cells, a 22% and 73% reduction in the population of B cells expressing s-IgM in the bone marrow and spleen, respectively, and a reduction in the percentage of B cells with s-IgD, indicating aberrant B cell differentiation
• bone marrow shows a decrease in immature B cells
• 50% decrease in the percentage of CD19+ B cells in the spleen
• 20% increase in the percentage of B cells in the bone marrow and an even greater increase in the peripheral blood
• bone marrow shows a 35% increase in the percentage of pre-B2 cells
• white blood cell count is higher than in wild-type mice
• 81% of mutants have enlarged spleens
• B cells do not undergo chemotaxis or morphological changes in response to the chemokine CXCL13

immune system
• marker analysis of early B-cell development indicates a 35% increase in the percentage of pre-B2 cells, a 22% and 73% reduction in the population of B cells expressing s-IgM in the bone marrow and spleen, respectively, and a reduction in the percentage of B cells with s-IgD, indicating aberrant B cell differentiation
• bone marrow shows a decrease in immature B cells
• 50% decrease in the percentage of CD19+ B cells in the spleen
• 20% increase in the percentage of B cells in the bone marrow and an even greater increase in the peripheral blood
• bone marrow shows a 35% increase in the percentage of pre-B2 cells
• white blood cell count is higher than in wild-type mice
• 81% of mutants have enlarged spleens
• B cells do not undergo chemotaxis or morphological changes in response to the chemokine CXCL13
• some mutants exhibit infiltrated leukocytes in the liver and the kidney, which contain a mixture of small T and B cells

liver/biliary system
• 56% of aged mutants exhibit hepatomegaly, with rough liver surfaces

cellular
• mouse embryonic fibroblasts exhibit smooth edges with few projections, reduced polarity, and altered actin cytoskeletal architecture compared with wild-type cells
• mouse embryonic fibroblasts (MEFs) exhibit impaired cell spreading during attachment compared with wild-type cells
• upon PDGF treatment, MEFs develop more prominent dorsal ruffles compared with wild-type cells
• MEFs exhibit 50% less internalization of transferrin compared with wild-type cells
• however, cell proliferation is normal
• mouse embryonic fibroblasts form poor focal adhesions compared with wild-type cells
• in 0.2% serum medium
• however, migration is restored by the addition of PDGF, EGF, or 10% serum

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
non-Hodgkin lymphoma DOID:0060060 OMIM:605027
J:186118


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
10/08/2019
MGI 6.14
The Jackson Laboratory